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The calcium-dependent tyrosine kinase (CADTK), also
known as Pyk2/RAFTK/CAKb/FAK2, is a cytoskeleton-
associated tyrosine kinase. We compared CADTK regu-
lation with that of the highly homologous focal adhesion
tyrosine kinase (FAK). First, we generated site-specific
CADTK mutants. Mutation of Tyr402 eliminated auto-
phosphorylation and significantly decreased kinase ac-
tivity. Mutation of Tyr881, a putative Src kinase phos-
phorylation site predicted to bind Grb2, had little effect
on CADTK regulation. Src family tyrosine kinases re-
sulted in CADTK tyrosine phosphorylation even when
co-expressed with the Tyr402/Tyr881 double mutant, sug-
gesting that Src/Fyn etc. phosphorylate additional tyro-
sine residues. Interestingly, CADTK tyrosine-phospho-
rylated FAK when both were transiently expressed, but
FAK did not phosphorylate CADTK. Biochemical exper-
iments confirmed direct CADTK phosphorylation of
FAK. This phosphorylation utilized tyrosine residues
other than Tyr397, Tyr925, or Tyr576/Tyr577, suggesting
that new SH2-binding sites might be created by CADTK-
dependent FAK phosphorylation. Last, expression of the
CADTK carboxyl terminus (CRNK) abolished CADTK
but not FAK autophosphorylation. In contrast, FAK car-
boxyl terminus overexpression inhibited both FAK and
CADTK autophosphorylation, suggesting that a FAK-de-
pendent cytoskeletal function may be necessary for
CADTK activation. Thus, CADTK and FAK, which both
bind to some, but not necessarily the same, cytoskeletal
elements, may be involved in coordinate regulation of
cytoskeletal structure and signaling.
In rat liver epithelial cells, epidermal growth factor-depend-
ent tyrosine phosphorylation occurs in two waves, the second
wave is attributable, in part, to an epidermal growth factor-
stimulated rise in intracellular calcium (1, 2). G protein-cou-
pled receptor agonists initiate a greater intracellular calcium
signal and more robust tyrosine phosphorylation (1, 3, 4). Pu-
rification and peptide sequencing of the responsible soluble
tyrosine kinase revealed a novel sequence highly related to the
focal adhesion tyrosine kinase, FAK1 (5, 6). We named this
second member of the cytoskeleton-associated tyrosine kinase
family, the calcium-dependent tyrosine kinase (CADTK) to de-
note a principle mechanism of regulation. At the same time,
four other groups identified this kinase and named it Pyk2 (7),
CAKb (8), RAFTK (9), and FAK2 (10). CADTK is activated by
a wide variety of hormones and other G protein-coupled recep-
tor agonists as well as pharmacological agents that raise intra-
cellular calcium or activate protein kinase C (6, 7, 11–15).
Additionally, growth factors (16–20), chemokines (21–24), cy-
tokines (25, 26), cell stress signals (6, 27, 28), and in some
instances cell adherence (23, 29–31), have all been shown to
activate CADTK in some cell types. Once activated, CADTK
has been implicated in the regulation of ion channels (7), ex-
tracellular signal regulated kinase (7, 12–14), c-Jun N-termi-
nal kinase (JNK) (6, 18, 22, 25, 27, 28, 32), and p70 S6 kinase
(p70S6K) (33). It has also been reported that CADTK may play
a role in Fyn-mediated T cell receptor (34, 35), Syk-mediated
FceRI receptor (36), and JAK3-mediated interleukin-2 receptor
signaling pathways (26). CADTK physically associates with
cytoskeletal proteins, such as paxillin and p130Cas (37–40), as
well as their homologues Hic5 (41), leupaxin (42), and
p105HEF1 (37), and may directly regulate their tyrosine phos-
phorylation in response to agonists as diverse as growth factors
and cell adherence (16, 23).
CADTK and FAK are highly homologous, sharing an overall
45% amino acid sequence identity with 60% identity in the
catalytic domain. Several tyrosine residues appear to be con-
served between CADTK and FAK, including a Src family tyro-
sine kinase SH2-binding site. Furthermore, CADTK, like FAK,
contains proline-rich motifs capable of SH3 domain interaction
and a putative focal adhesion targeting domain. Immuno-
staining of CADTK and expression of GFP-tagged CADTK re-
vealed that CADTK localizes to the focal adhesion region. In
cells expressing both FAK and CADTK, both proteins appear to
co-localize near the focal adhesion membrane attachment sites,
however, CADTK extends further into the cell, e.g. CADTK
extends onto actin stress fibers in smooth muscle cells (16).2
Given the high degree of structural and amino acid sequence
similarity, CADTK and FAK may well have some similar or
even interchangeable biological functions. In fact, well studied
mouse fibroblast cell lines appear to express only FAK and not
CADTK. In contrast, we and others have recently shown that
normal circulating monocytes, as well as T and B cells, express
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only CADTK (23, 24). Thus certain cells can function with only
one of these two cytoskeleton-associated kinases. Conversely,
since both proteins are often co-expressed in mesenchymal
cells, multiple epithelial cells, neural cells and tissues, and
endothelial cells (6, 7, 14, 16, 39, 43), they presumably have
distinct functions as well. When expressed together the major
difference between the two enzymes was easily detected, FAK
is constitutively active in resting, adherent cells while CADTK
is dephosphorylated and inactive until stimulated by agonists,
i.e. CADTK regulation is more dynamic in the sense that it
rapidly responds to extracellular signals.
In this report, we examined the tyrosine autophosphoryla-
tion and tyrosine kinase activity of CADTK and variants con-
structed by site-directed mutagenesis and compare them to
previous structure/function data obtained with FAK. CADTK
and FAK were tyrosine phosphorylated by Src family tyrosine
kinases; the sites of CADTK are not necessarily those previ-
ously thought to be Src targets on FAK. Intriguingly, we
showed that CADTK tyrosine phosphorylated FAK both in vivo
and in vitro while FAK did not phosphorylate CADTK. Again,
sites other than major autophosphorylation or putative Src
target site appeared to be involved. Last, by transiently co-
expressing the carboxyl terminus of CADTK (CRNK) and the
carboxyl terminus of FAK (FRNK) with wild type CADTK or
FAK, we demonstrated that FRNK inhibited both FAK and
CADTK tyrosine autophosphorylation, while CRNK inhibited
only CADTK autophosphorylation. Our results demonstrate
that although CADTK and FAK are regulated differentially in
cells expressing both proteins, they may, additionally, influ-
ence signal transduction from the other family member.
EXPERIMENTAL PROCEDURES
Materials—Yes and Y527F Src were kindly provided by Drs. Nancy
Rabb-Traub, and Channing Der (University of North Carolina at
Chapel Hill), respectively. Fyn, Lck, Syk, and Zap70 were generously
provided by Dr. Andre Veillette (McGrill University). Polyclonal anti-
CADTK antibody was described previously (6), anti-HA monoclonal
antibody and anti-FAK (C-20, A-17) were purchased from Boehringer
Mannheim and Santa Cruz Biotechnology, respectively. Human 293(T)
cells were grown in Dulbecco’s modified Eagle’s medium with 10% fetal
bovine serum as described previously (39).
Site-directed Mutagenesis—Rat wtCADTK cDNA was used as a tem-
plate to generate a series of CADTK mutants based on polymerase
chain reaction site-directed mutagenesis strategy (Stratagene). Mu-
tated CADTK cDNAs were amplified by Pfu DNA polymerase (Strat-
agene) with complementary DNA mutagenic oligonucleotides for de-
signed mutations (K457A, D567N, Y402F, Y881F, K457A/Y402F,
Y579F/Y580F CADTK). The human FAK cDNA was used to make the
mutants Y397F, Y576F/Y577F, and Y925F FAK by the same method.
All the mutants were confirmed by DNA sequence analysis (University
of North Carolina, Sequence Facility).
Cell Lysate Preparation—Cell lysates were prepared essentially as
described previously (5). Briefly, cells treated with agonists were
scraped into ice-cold cell lysis buffer (150 mM NaCl, 20 mM Tris (pH 7.5),
1% Triton X-100, 5 mM EDTA, 50 mM sodium fluoride, and 10%(v/v)
glycerol with freshly added 1 mM Na3VO4, 20 mg/ml phenymethylsulfo-
nyl fluoride, 10 mg/ml leupeptin, and 100 kallikrein inhibitor units of
aprotinin/ml). Cell lysates were clarified by centrifugation and their
protein content determined by Coomassie protein assay reagent
(Pierce).
cDNA Transient Expression in Human 293(T) Cells—pcDNA3 vector
(Invitrogen), pcDNA3-CADTK, pcDNA3-wtCADTK, pcDNA3-FAK,
pCMV-FRNK, pcDNA3-Yes, PXM139-Fyn, Lck, Syk, and ZAP70 were
transfected or co-transfected into human 293(T) cells with Fugene6
according to the manufacturer’s procedure (Boehringer Mannheim).
After 48 h, transfected cells were harvested and lysed, and the lysates
were analyzed by immunoprecipitation, followed by immunoblotting
with anti-Tyr(P), anti-CADTK, anti-FAK, or by a tyrosine kinase activ-
ity assay.
Immunoprecipitation and Immunoblotting—In a typical experiment,
;500 mg of cell lysate was immunoprecipitated by incubation with the
antibody for 2 h at 4 °C. 20 ml of protein A-agarose beads were then
added for 1 more hour. Immune complexes were collected by centrifu-
gation, washed three times with lysis buffer, and resuspended in SDS-
PAGE sample buffer. Samples were subjected to SDS-PAGE, trans-
ferred to Immobilon (Millipore), and incubated with the selected
antibody. Immunoblots were developed with ECL according to the man-
ufacturer’s procedure (Amersham). Immunoblots were stripped in
buffer (62.5 mM Tris (pH 6.8), 2% SDS, 100 mM b-mercaptoethanol) at
50 °C for 30 min and reprobed with another antibody.
Tyrosine Kinase Activity Assay—Immune complex tyrosine kinase
and autokinase assays were performed as previously reported (3).
Briefly, immune complex suspensions were preincubated for 5 min at
4 °C with 160 mg of the synthetic tyrosine kinase substrate poly(Glu4:
Tyr) (Sigma) or the control substrate poly(Glu). Additional experiments
were performed using a GST NH2 terminus of human FAK fusion
protein encompassing amino acids 1 to 426 (5 mg per assay) as a
substrate. Reactions (80 ml of total reaction volume) were initiated by
adding of 5 mCi of [g-32P]ATP (5 mM) After 15 min at 25 °C, 50 ml of the
reaction mixture was spotted on P81 Whatman paper. The papers were
washed once with 10 mM sodium pyrophosphate in 10% trichloroacetic
acid and twice with 5% trichloroacetic acid, air-dried, and assayed by
liquid scintillation counting. For GST NH2-terminal FAK phosphoryl-
ation, the assays were stopped with SDS stop solution, run on 8%
SDS-polyacrylamide gels, and subjected to autoradiography. Assess-
ment of the ability of CADTK and FAK to directly cross-phosphorylate
was performed using an in vitro tyrosine phosphorylation assay.
Briefly, CADTK-GFP, kdCADTK, kdFAK, and control vector were tran-
siently expressed in 293(T) cells, independently. Equal amounts of cell
lysates were mixed before adding specific antibodies. Cell lysate mix-
tures were incubated at 4 °C for 2 h followed by addition of protein
A/G-agarose beads. Immunocomplexes were washed three times with
lysis buffer and once with kinase assay buffer before providing
[g-32P]ATP. Reaction mixtures were incubated at 25 °C for 15 min.
After removing the supernatant, SDS-PAGE sample loading buffer was
added to the immunocomplexes and they were subjected to SDS-PAGE
and autoradiography. These experiments were repeated using wild type
CADTK and separating phosphorylated CADTK (p115) and FAK
(p125) on 8% low bis-acrylamide gels and by immunoprecipitating both
CADTK-GFP and kdFAK, using buffers with 0.1% SDS in the washes.
RESULTS
Site-directed Mutagenesis: Analysis of Tyrosine Autophos-
phorylation and Tyrosine Kinase Activity of CADTK Mutants—
Tyr397 is a major FAK tyrosine autophosphorylation site (44).
Mutation of this site dramatically inhibited FAK tyrosine au-
tophosphorylation and decreased tyrosine kinase activity by
50% (45). Autophosphorylated Tyr397 serves as an SH2 domain
docking site for the recruitment of Src family tyrosine kinases
(44, 46–48), which in turn may tyrosine phosphorylate FAK on
Tyr925 (49) or other tyrosine residues (45). Guided by amino
acid sequence similarity to FAK, we mutated homologous
CADTK tyrosine residues to investigate their effects on
CADTK tyrosine phosphorylation and kinase activity. In addi-
tion, to create “kinase deficient” CADTK, we separately mu-
tated two CADTK residues important in Mg21-ATP binding,
Lys457 and Asp567, changing them to Ala and Asn, respectively.
For comparison, we also made similar mutations in the human
FAK cDNA.
Both wild type and mutant cDNAs were transiently ex-
pressed in 293(T) cells and their tyrosine autophosphorylation
and kinase activity was assessed. As shown in Fig. 1A, muta-
tion of the CADTK Mg21-ATP-binding site residues (K457A or
D567N) abolished tyrosine kinase activity as assessed by poly-
(Glu4:Tyr) phosphorylation as well as CADTK tyrosine auto-
phosphorylation (Fig. 1B), suggesting that these two residues
are each required for CADTK kinase activity. Mutation of
Tyr402 (corresponding to the Src family binding site, Tyr397)
also abolished CADTK tyrosine autophosphorylation, severely
depressing but not completely inhibiting tyrosine kinase activ-
ity (;70% decrease). These data suggest that Tyr402, like
Tyr397 in FAK, is the major tyrosine autophosphorylation site.
Its phosphorylation is important but not absolutely required
for tyrosine kinase activity. Mutation of adjacent tyrosine res-
idues Tyr579/Tyr580 in the catalytic domain of CADTK (corre-
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sponding to FAK Tyr576/Tyr577) significantly decreased
CADTK tyrosine autophosphorylation and reduced kinase ac-
tivity by ;60%. These data, taken together with the Y402F
mutant data, suggest that Tyr579/Tyr580 are not major tyrosine
autophosphorylation sites but that transient tyrosine phospho-
rylation of these sites may be required for full or continued
CADTK activation.
Mutation of Tyr881 (corresponding to FAK Tyr925, the site of
Grb2 SH2 domain association) had little or no effect on CADTK
tyrosine autophosphorylation or tyrosine kinase activity. Thus,
autophosphorylation appears to involve Tyr402 but not Tyr881.
Finally, double mutants, K457A/Y402F and Y402F/Y881F, pro-
duced the same effect as the single mutants, K457A and
Y402F, respectively, suggesting that the single mutation of
K457A and Y402F produced the dominant effect. CADTK ty-
rosine kinase activity and tyrosine autophosphorylation data
were generally concordant, indicating that tyrosine phospho-
rylation correlates with kinase activity. Comparison of the
effects of corresponding CADTK and FAK mutations (45), sug-
gests that the structure-function regulatory mechanisms of
these two tyrosine kinases are similar.
To further examine the regulation of these two kinases, the
kinase-deficient CADTK (kdCADTK), K457A CADTK, and ki-
nase-deficient FAK (kdFAK) K454A FAK were transiently co-
expressed with the Src family tyrosine kinase members, Src,
Fyn, Yes, and Lck. As shown in Fig. 2, Src, Fyn, and Yes
dramatically increased CADTK (Fig. 2A) and FAK (Fig. 2B)
tyrosine phosphorylation, while Lck had little effect (particu-
larly on CADTK). These data suggest that CADTK and FAK
signaling may be similarly affected by Src family tyrosine ki-
nases, presumably by phosphorylation of conserved tyrosine
residues. However, Src and Fyn were also capable of substan-
tially phosphorylating the Y402F/Y881F CADTK double mu-
tant (Fig. 2C), suggesting that other tyrosine residue(s) must
be significant targets for Src family tyrosine kinases. Moreover,
at least when co-expressed, neither activated Src, wild type
Fyn, nor Yes required a Tyr402 docking site on CADTK to
tyrosine phosphorylate CADTK. Last, transient co-expression
of two important hematopoietic cytoplasmic tyrosine kinases,
Syk or ZAP70, with kdCADTK did not increase their tyrosine
phosphorylation (data not shown), suggesting that Syk and
ZAP70 cannot directly phosphorylate CADTK under these ex-
perimental conditions.
CADTK Tyrosine Phosphorylates FAK in Vivo and in Vitro—
Receptor tyrosine kinases from the epidermal growth factor
receptor family form heterodimers and cross-phosphorylate
each other (50). To test whether CADTK and FAK can also
associate and cross-phosphorylate, kdCADTK and kdFAK were
transiently co-expressed in human 293(T) cells with wild type
FAK or CADTK, respectively. Immunoprecipitation with spe-
cific antibodies followed by phosphotyrosine immunoblotting
showed that CADTK significantly increased kdFAK tyrosine
phosphorylation (Fig. 3A). Similar results were obtained with
co-expression of either wtCADTK or CADTK-GFP (a fusion
protein with a green fluorescence protein fused to the CADTK
carboxyl terminus) and kdFAK (Fig. 3A). In contrast, FAK
FIG. 1. Tyrosine kinase activity and autophosphorylation of
CADTK and its mutants. Wild type CADTK and its mutants were
independently transfected into 293(T) cells. After 48 h, each was im-
munoprecipitated with anti-CADTK antibody. A, tyrosine kinase activ-
ity assays were performed using poly(Glu4:Tyr) as a substrate and
measuring 32P incorporation as described under “Experimental Proce-
dures.” B, immunoprecipitated samples were subjected to SDS-PAGE
and immunoblotted with anti-Tyr(P) antibody. The blot was then
stripped and reblotted with anti-CADTK antibody. These data are
representative of three independent experiments.
FIG. 2. Src family tyrosine kinases phosphorylate both CADTK
and FAK in vivo. Src family tyrosine kinases (Src, Fyn, Yes, and Lck)
were co-transfected with kinase-deficient CADTK (kdCADTK) or ki-
nase-deficient FAK (kdFAK), respectively. kdCADTK (A) and kdFAK
(B) were immunoprecipitated, subjected to SDS-PAGE, and immuno-
blotted with an anti-Tyr(P) antibody. Blots were stripped and reblotted
with anti-CADTK and anti-FAK antibodies, respectively. C, kdCADTK
or Y402F/Y881F CADTK were co-expressed with Src or Fyn in 293(T)
cells. CADTK was immunoprecipitated with anti-CADTK antibody and
subjected to anti-Tyr(P) followed by anti-CADTK immunoblotting.
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failed to phosphorylate kdCADTK (Fig. 3B). Interestingly, we
could not detect physical association between these two tyro-
sine kinases (data not shown), i.e. immunoprecipitation (even
using reduced ionic strength buffer) of either enzyme from the
dual transfected cells did not reveal the other protein. Under
the same conditions we have easily detected complexes of
CADTK and cytoskeletal proteins or other SH3 containing
proteins (39). Therefore, CADTK results in tyrosine phospho-
rylation of kdFAK without forming lasting CADTK:FAK
heterodimers.
Since the co-expression of CADTK could have activated an
endogenous third tyrosine kinase resulting in kdFAK phospho-
rylation, we investigated CADTK:FAK cross-phosphorylation
in vitro. To separate CADTK and FAK on SDS-PAGE, we used
CADTK-GFP, which has a molecular mass of ;145 kDa, and
similar tyrosine autophosphorylation and kinase activity when
compared with wtCADTK (data not shown). Transient expres-
sion of CADTK-GFP, kdFAK, kdCADTK, and control vector
were performed individually in 293(T) cells. Equal amounts of
cell lysate from the indicated pair of transfected cells were
combined and incubated with two antibodies, one directed
against the NH2 terminus of CADTK and one against the NH2
terminus of FAK. Subsequently, protein A/G-agarose beads
were added and the indicated pairs of transfected proteins or
transfected protein and control were precipitated, washed, and
in vitro phosphorylation was performed using [g-32P]ATP. Fol-
lowing SDS-PAGE, autoradiography showed that CADTK-GFP
facilitated the incorporation of 32P into kdFAK, suggesting
direct in vitro phosphorylation of FAK by CADTK-GFP (Fig.
3C). Interestingly, CADTK-GFP only weakly phosphorylated
kdCADTK in vitro, suggesting that, at least for intermolecular
phosphorylation, FAK may be a preferred substrate. Thus,
CADTK can tyrosine phosphorylate FAK both in vivo and in
vitro suggesting that agonist-dependent (e.g. angiotensin II,
lysophosphatidic acid, etc.) increases in FAK phosphorylation
in cells expressing and co-localizing both enzymes may be at-
tributed, in part, to CADTK-dependent FAK tyrosine
phosphorylation.
We next examined whether CADTK-dependent FAK tyro-
sine phosphorylation resulted in increased FAK tyrosine ki-
nase activity as measured by phosphorylation of poly(Glu4:
Tyr). First, co-expression of FAK and CADTK followed by
immunoprecipitation of FAK showed that CADTK can increase
tyrosine phosphorylation of wtFAK (Fig. 4B) in addition to its
phosphorylation of kdFAK (Fig. 3). Second, assessment of in
vitro kinase activity showed an increase in FAK tyrosine ki-
nase activity (30–40%) (Fig. 4A). This was clearly less than the
;5–10-fold CADTK-dependent increase in FAK tyrosine phos-
FIG. 3. CADTK phosphorylated FAK in vivo and in vitro, but
not vice versa. A, CADTK or CADTK-GFP were co-expressed with
kdFAK in 293(T) cells. kdFAK was immunoprecipitated with anti-FAK
antibody. Immunocomplexes were subjected to SDS-PAGE and immu-
noblotted with anti-Tyr(P) antibody. The blot was stripped and reblot-
ted with anti-FAK antibody. B, wtFAK were co-transfected with
kdCADTK in 293(T) cells. kdCADTK was immunoprecipitated with
anti-CADTK antibody and analyzed for anti-Tyr(P) and anti-CADTK.
The samples were also immunoprecipitated with anti-FAK antibody
and blotted with anti-Tyr(P) antibody, showing that FAK was tyrosine
phosphorylated by co-transfection. C, CADTK-GFP, kdFAK, kdCADTK,
and pcDNA3 vector were transfected into 293(T) cells, respectively.
After lysis, equal amounts of cell lysates were mixed as indicated, and
immunoprecipitated with NH2-terminal anti-CADTK and anti-FAK an-
tibodies. After washing, in vitro immunocomplex kinase assays were
performed labeling with [g-32P]ATP. Phosphotyrosine was analyzed by
SDS-PAGE, followed by autoradiography.
FIG. 4. CADTK-dependent stimulation of FAK tyrosine kinase
activity and phosphorylation. In three separate transfections, wt-
FAK was co-expressed with vector or CADTK in 293(T) cells. FAK was
immunoprecipitated with anti-FAK antibody. A, FAK kinase activity
was measured by using poly(Glu4:Tyr) as a substrate as described
under “Experimental Procedures.” B, the immunocomplexes were sub-
jected to SDS-PAGE and blotted with anti-Tyr(P) antibody, then
stripped and reblotted with anti-FAK antibody.
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phorylation (Fig. 4B). This result (Fig. 4) obtained with tripli-
cate, independent transfections was typical of multiple exper-
iments in which the increase in FAK tyrosine kinase activity
was much less than the increase in CADTK-dependent FAK
tyrosine phosphorylation. Since poly(Glu4:Tyr) is not a a phys-
iologic substrate, the experiment, was repeated, using a GST
FAK NH2-terminal fusion protein that included Tyr
397 as a
substrate for wild type FAK precipitated from vector or CADTK
transfected cells. The CADTK-dependent tyrosine phosphoryl-
ation of FAK in co-transfected cells was again increased dra-
matically (Fig. 5A), but autokinase activity (32P incorporation
into FAK in vitro, Fig. 5C) and substrate phosphorylation (32P
incorporation into GST NH2-terminal FAK, Fig. 5D) was only
increased ;50–100%. Thus using 2 substrates, poly(Glu4:Tyr)
and GST NH2-terminal FAK, CADTK-dependent FAK phos-
phorylation is greater than the activation of FAK kinase. Be-
cause the kinase activity of FAK in adherent cells has seldom
been reported to change dramatically, it is unclear what an
;50% change in kinase activity means. However, the substan-
tial increase in kdFAK or wtFAK tyrosine phosphorylation
upon co-transfection suggests that CADTK may indeed regu-
late FAK tyrosine phosphorylation in vivo. Because FAK is in
part a structural protein whose function is to localize SH2-
containing domain proteins, increased FAK tyrosine phospho-
rylation may have physiologic consequences.
We investigated the potential CADTK-dependent tyrosine
phosphorylation sites on FAK by co-transfecting wtCADTK
and FAK mutants, kdFAK, Y397F, Y576F/Y577F, and Y925F
FAK in 293(T) cells (Fig. 6). Transiently expressed CADTK
phosphorylated all FAK mutants in vivo suggesting CADTK-
dependent FAK tyrosine phosphorylation may occur on other
sites in addition to the well studied tyrosine residues. Taken
together, these data suggest that CADTK may potentially func-
tion as an upstream regulator of FAK by directly phosphoryl-
ating FAK, slightly increasing its tyrosine kinase activity, and
generating more or even new sites for the recruitment of SH2
containing proteins.
Overexpression of FRNK Inhibited FAK and CADTK Tyro-
sine Autophosphorylation while Overexpression of CRNK
Blocked Only CADTK Tyrosine Phosphorylation—Alternative
RNA splicing of the FAK primary transcript can yield a 43-kDa
species encoding the carboxyl terminus of FAK initiated just
beyond the tyrosine kinase domain (51). Overexpression of this
protein, termed FRNK (FAK-related non-kinase), inhibits FAK
activity, presumably by displacing FAK (52) and in some man-
ner blocking the formation of focal adhesions on fibronectin (53,
54). FRNK probably acts by competing for FAK binding part-
ners through FRNK’s focal adhesion targeting domain, the
sequence both necessary and sufficient for FAK recruitment to
the focal adhesion (55). CADTK shares 60% homology with
FAK in the carboxyl terminus. While not yet detected as an
expressed protein, CADTK has a methionine residue as a po-
tential start site for an alternatively spliced product analogous
to FRNK. This has been termed CRNK (CADTK or CAKb-
related non-kinase, pronounced “crank”) by our colleague, Mi-
chael Schaller (56). Since CADTK activation, like FAK, re-
quires an intact engaged cytoskeleton (23, 39), we created a
CRNK construct in pcDNA3 to investigate whether CRNK
overexpression inhibited CADTK tyrosine autophosphoryla-
tion. When co-expressed CRNK blocked CADTK tyrosine auto-
phosphorylation (Fig. 7A); i.e. CRNK functions similarly to
FRNK and negatively regulates CADTK autophosphorylation.
In contrast, co-expression of FAK and CRNK did not alter FAK
tyrosine autophosphorylation (Fig. 7B), suggesting that under
these conditions of co-expression of CRNK, inhibition was spe-
cific for CADTK, presumably because its sequence is not simi-
lar enough to FRNK to displace FAK. As expected, FRNK
inhibited FAK activity when co-expressed (Fig. 7B) but, unex-
pectedly, FRNK co-expression dramatically inhibited CADTK
tyrosine autophosphorylation (Fig. 7A). Thus, FRNK regulates
both CADTK and FAK activation under these conditions; how-
ever, the mechanisms by which FRNK acts may not be the
FIG. 5. CADTK-dependent phosphorylation and FAK autoki-
nase activity. Following duplicate transfections (vector and wtFAK
(lanes 1 and 2) and CADTK and wtFAK (lanes 3 and 4)), FAK was
immunoprecipitated and the immune complex analyzed. A, phosphoty-
rosine immunoblotting demonstrated substantial CADTK-dependent
FAK tyrosine phosphorylation. B, similar amounts of FAK were immu-
noprecipitated in each sample as demonstrated by stripping and re-
probing with anti-FAK (C20) antibody. C, another portion of each im-
mune complex was incubated with [g-32P]ATP and GST NH2-terminal
FAK, (1–423) as described under “Experimental Procedures. The auto-
radiograph shows FAK autophosphorylation was increased slightly by a
CADTK-dependent action. D, FAK kinase activity toward an exogenous
substrate, GST NH2-terminal FAK was also minimally increased. FAK
parallel FAK-dependent poly(Glu4:Tyr) phosphorylation by these im-
mune complexes showed an average of 14,366 cpm from samples 1 and
2 and 19,964 cpm from samples 3 and 4.
FIG. 6. CADTK phosphorylated FAK on tyrosine phosphoryla-
tion sites other than Tyr397, Tyr576/Tyr577, and Tyr925. Several
mutant FAK constructs were co-transfected with CADTK or pcDNA3
vector in 293(T) cells as indicated. FAK was immunoprecipitated and
subjected to SDS-PAGE. After transfer and immunoblotting with anti-
Tyr(P), the blot was stripped and reprobed with anti-FAK antibody.
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same for the two cytoskeleton-associated kinases.
The specific mechanisms of CADTK or FAK activation re-
main elusive. In resting, adherent cells, FAK is constitutively
activated by the process of adherence, while CADTK is “off” in
resting adherent cells, but is rapidly activated by agonists.
Transient overexpression of CADTK in 293(T) and other cells
using a strong promoter results in CADTK activation in resting
cells without the addition of an agonist. This presumably oc-
curs by one of several mechanisms potentially including: (i)
overexpression-dependent movement of CADTK into an acti-
vating binding site or (ii) by overcoming a saturable negative
regulation system such as a constitutively activated tyrosine
phosphatase that removes CADTK activating tyrosine phos-
phorylation. To investigate this, we co-expressed CADTK and
vector or CADTK and CRNK and pretreated cells with per-
vanadate (5 min), a technique known to inhibit most, if not all,
tyrosine phosphatases. Treatment with pervanadate resulted
in a substantial increase (10–20-fold) in CADTK tyrosine phos-
phorylation (Fig. 8), indicating that there is a vast pool of
underphosphorylated CADTK in the transfected cells. CRNK,
as previously shown, inhibited the autophosphorylation of
CADTK stimulated by overexpression but did not significantly
depress CADTK phosphorylation in cells pretreated with per-
vanadate. That CRNK does not block activation by pervana-
date suggests that at least two mechanisms of CADTK activa-
tion, one dependent on cellular binding and localization (this
“site” can be accessed by transient CADTK overexpression and
blocked by CRNK co-expression) and another mechanism de-
pendent on suppression of phosphatase activity. The latter is
not detectably influenced by CRNK.
DISCUSSION
The discovery and isolation of CADTK, the second member of
the FAK family of tyrosine kinases, raised questions about how
this kinase is regulated in comparison to FAK, and whether the
two family members interact as do some receptor tyrosine
kinase family members. In this report, we show that, 1) the
structure-function relations governing CADTK tyrosine auto-
phosphorylation and kinase activity are similar to those of
FAK, at least superficially (Fig. 1); 2) CADTK and FAK are
both direct targets of Src family tyrosine kinases; and CADTK
contains Src-phosphorylated tyrosine residue(s) in addition to
the Tyr881, identified as a FAK Tyr925 equivalent (Fig. 2); 3)
CADTK directly cross-phosphorylates FAK slightly increasing
FAK tyrosine kinase activity and perhaps creating novel phos-
photyrosine sites as targets for SH2 group-containing proteins
(Figs. 3–6); 4) FAK does not cross-phosphorylate CADTK un-
der the conditions tested (Fig. 3B); 5) the carboxyl terminus of
CADTK (CRNK) can inhibit CADTK but not FAK tyrosine
autophosphorylation, presumably by displacing CADTK from
its cytoskeleton-binding sites (Fig. 7A); and 6) overexpression
of FRNK abolishes both FAK and CADTK tyrosine autophos-
phorylation (Fig. 7B).
The major CADTK tyrosine autophosphorylation site is
Tyr402; mutation of this site abolished CADTK tyrosine auto-
phosphorylation and substantially inhibited its kinase activity
(Fig. 1). The role of Tyr402 phosphorylation in full activation of
the kinase may result from two (or more) potential mecha-
nisms. First, tyrosine autophosphorylation of Tyr402 may mod-
ify CADTK structure by opening or keeping the catalytic cleft
open thereby promoting substrate access. Second, phospho-
Tyr402 may recruit Src family tyrosine kinases to further in-
crease CADTK kinase activity. We doubt that these results (the
difference between wtCADTK and Y402F CADTK) are con-
founded by associated Src family tyrosine kinases (or other
co-precipitated endogenous kinases) because these experi-
ments have been repeated using RIPA buffer containing SDS,
which reverses the association with other molecules, e.g. Src
family tyrosine kinases. We attempted to test the first hypoth-
esis by introducing a permanent negative charge at this site by
mutating Tyr402 to aspartic acid (Y402D). As expected, the
Y402D mutation was not autophosphorylated, but the reduc-
tion of CADTK immunocomplex kinase activity was similar to
FIG. 7. Overexpression of CRNK only inhibited CADTK auto-
phosphorylation, while overexpression of FRNK inhibited both
CADTK and FAK tyrosine phosphorylation. wtCADTK or FAK
were co-expressed with CRNK, FRNK, or pcDNA3 vector in 293(T)
cells, respectively. A, CADTK was immunoprecipitated with anti-
CADTK antibody and analyzed with anti-Tyr(P) and anti-CADTK an-
tibodies to determine CADTK autophosphorylation, CADTK and CRNK
expression. Samples were also analyzed for FRNK expression. B, FAK
was immunoprecipitated with anti-FAK antibody, and its phosphoryl-
ation and expression level was analyzed using anti-Tyr(P) and anti-
FAK antibodies.
FIG. 8. CADTK activation by pervanadate pretreatment is not
inhibited by CRNK. wtCADTK was co-expressed with vector or
CRNK in 293(T) cells. 48 h after transfection, cells were treated with or
without pervanadate (100 mM H2O2/Na3VO4) for 5 min. Cell lysates
were prepared and immunoprecipitated with anti-CADTK antibody.
Immunocomplexes were analyzed with anti-Tyr(P) and anti-CADTK
antibodies.
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that of the Y402F mutant (data not shown). Whether this is an
adequate test of this hypothesis is unclear. The negatively
charged aspartate which has been shown to mimic activating
phosphoserines in some kinases (e.g. MEK) (57) may not be
spatially equivalent to the negative charge provided by phos-
phate on the tyrosyl ring.
In addition to Tyr402, full activation of CADTK requires
tyrosine phosphorylation of two other tyrosine residues (Tyr579
and Tyr580) in the catalytic domain. Mutation of these two
residues decreased CADTK tyrosine autophosphorylation and
kinase activity by 60%. Unlike the Y402F mutation, the Y579F/
Y580F CADTK mutant exhibited partial tyrosine autophospho-
rylation when overexpressed, suggesting that the residual
Y579F/Y580F CADTK kinase activity autophosphorylates
Tyr402. Surprisingly, there is no Tyr579/Tyr589 tyrosine phos-
phorylation in the Y402F mutant despite detectable tyrosine
kinase activity (Fig. 1A). Tyrosines 579 and 580 lie within the
catalytic domain at a position that is conserved among many
but not all protein tyrosine kinase families (58). In some in-
stances, phosphorylation of these residues is obligatory for
tyrosine kinase activation (e.g. insulin receptor) (59, 60). As
noted above, it has been proposed that tyrosine phosphoryla-
tion of FAK Tyr397 provides an SH2-binding site for Src family
tyrosine kinases (44, 46–48) which in turn phosphorylate
Tyr576 and Tyr577 and further increase tyrosine kinase activity
(45). While CADTK Y579F/Y580F does have slightly higher
autophosphorylation and kinase activity than Y402F, it seems
unlikely that the difference is due to endogenous Src/Fyn acti-
vation of overexpressed CADTK. It seems more likely that both
Tyr402 and Tyr579/Tyr580 tyrosine phosphorylation are inde-
pendently important for opening and/or maintaining the active
conformation of the kinase. Construction and assessment of a
Tyr402/Tyr579/Tyr580 triple mutant will help to resolve this
issue.
CADTK phosphorylates FAK but does not form heterodimers
in vivo. These data suggest that CADTK may be an agonist-
dependent regulator of FAK. Agonist stimulation in most cells
slightly increases FAK tyrosine phosphorylation (by ;50% in
rat liver epithelial and smooth muscle cells) (5, 16, 39). In
addition, agonist-dependent tyrosine phosphorylation of paxil-
lin, tensin, and p130Cas) is better correlated with CADTK than
FAK activation (39). The increase in FAK phosphorylation
complicates the analysis of which enzyme is responsible for
agonist-dependent paxillin tyrosine phosphorylation. It may
even be that increased CADTK (Tyr402) and FAK (Tyr397) phos-
phorylation induces Src activation which is primarily respon-
sible for agonist-dependent cytoskeletal protein phosphoryla-
tion. CADTK can phosphorylate FAK on sites in addition to
Tyr397 and Tyr925 (Fig. 6) raising the possibility that new
docking sites for SH2 containing proteins are generated on
FAK. The increase in CADTK-dependent FAK phosphorylation
is clearly greater than its effect on FAK kinase activity. In
summary, agonist-dependent CADTK activation may alter
FAK activity and function, adding more complexity to cytoskel-
eton regulation in cells expressing both enzymes. While, we
cannot rule out that CADTK-dependent FAK tyrosine phospho-
rylation in vivo may be due to another tyrosine kinase, it is a
direct effect in vitro in an immune complex. In addition, the
fact that autophosphorylated wtFAK, which associates with
Src family tyrosine kinases, fails to induce CADTK tyrosine
phosphorylation in vivo, suggests, that the role of Src family
tyrosine kinases in CADTK and FAK cross-phosphorylation is
limited.
Like FAK, CADTK tyrosine phosphorylation can be regu-
lated by its CRNK (Fig. 7A). Neither finding (FRNK inhibiting
FAK or CRNK inhibiting CADTK) can explain the physiologi-
cal mechanism of activation by adhesion or agonists, but these
results suggest that access to a specific binding site is crucial
for activation. While CRNK only inhibited CADTK autophos-
phorylation, FRNK inhibits both FAK and CADTK autophos-
phorylation. This initially suggested that the FRNK sequence
is better able to displace both FAK and CADTK from crucial
sites. However, we previously showed that cytoskeleton en-
gagement is necessary for agonist-dependent CADTK activa-
tion; i.e. CADTK is not activated in suspended monocytes, rat
liver epithelial, or smooth muscle cells (23). Thus, FRNK could
influence CADTK through its established action, displacing
FAK from focal contacts. This might change focal contact func-
tion or structure, preventing CADTK activation by inhibiting a
crucial “permissive step.” CADTK and CRNK have a higher
affinity for paxillin than does FAK (39); talin, which physically
associates with FAK (61), does not interact with CADTK (62).
This reinforces a model in which CRNK and FRNK, which have
different target affinities, may act differently to regulate
CADTK. Said simply, CRNK may displace CADTK from its site
of activation, while FRNK may displace FAK, making the cells
behave as if they were in suspension.
It is unclear why overexpression of CADTK results in its
activation, but it does so in 293(T) (Fig. 8), as well as in HeLa,
MCF10, and NIH3T3 cells (data not shown). Our best expla-
nation is that overexpressed CADTK molecules access activa-
tion sites or effectors that overcome the physiologic proclivity to
be “off” in resting adherent cells. Substantial additional
CADTK activation by phosphatase inhibition (pervanadate)
demonstrates that only a small proportion of CADTK is acti-
vated by overexpression. A large inactive pool of overexpressed
CADTK, perhaps located in the cytoplasm, can be activated by
pervanadate (Fig. 8). The small pool of activated CADTK can be
completely inhibited by CRNK, presumably by displacement
from activating protein-protein interactions. Although we can-
not rule out a mechanism by which CRNK activates a CADTK-
specific phosphatase, we favor the above explanation.
In summary, our results suggest that CADTK and FAK, at
some level, participate in “cross-talk.” CADTK directly phos-
phorylates FAK, possibly generating more SH2 docking sites.
This may enhance physiologic control mechanisms in response
to agonists in some cells. In turn, FAK may be necessary for
CADTK activation in some adherent cells. This requirement
cannot be absolute since FAK is not present when adherence
activates CADTK in monocytes and the T cell receptor acti-
vates CADTK in T cells. Nevertheless, epithelial, neural,
smooth muscle, and endothelial cells, may use these two mech-
anisms of CADTK-FAK interaction to orchestrate cytoskeleton
regulation of morphology and signaling in response to agonist
stimulation and extracellular matrix.
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